Publication | Open Access
Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first‐line treatment of advanced esophageal squamous cell carcinoma
135
Citations
31
References
2020
Year
This trial was registered on July 27, 2018, at ClinicalTrials.gov (identifier: NCT03603756).
| Year | Citations | |
|---|---|---|
Page 1
Page 1